Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, Hackensack University Medical Center, shared a post on X:
“WU-KONG1B for EGFR exon 20 Journal of Clinical Oncology from James Yang, Pasi Jänne et al.
Take: Exon 20 is the hardest EGFR to treat. Sunvozertinib orally joins ami and dato. ORR ~45%, DOR ~13m. Waterfall plots easy to read from far away.”
Title: Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Authors: James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, Yun Fan, Dongqing Lv, Meili Sun, Dingzhi Huang, Laurent Greillier, David Planchard, Qunying Hong, Julien Mazieres, Enriqueta Felip, Xingya Li, Ying Hu, Jian Fang, Lyudmila Bazhenova, François Ghiringhelli, Manuel Angel Cobo Dols, Luis Paz-Ares Rodriguez, Alessandra Bearz, Bruna Pellini, Yu Jung Kim, Joaquim Bosch-Barrera, Byoung-Yong Shim, Yung-Hung Luo, Marcello Tiseo, Tsung-Ying Yang, Enric Carcereny, Regan M. Memmott, Gerard Zalcman, Javier de Castro Carpeno, Vincenzo Di Noia, Hector Soto Parra, Guillermo Streich, Dae Ho Lee, Elaine Shum, Ji-Youn Han, Jesus Corral Jaime, Daniel Brungs, Thomas John, Manolo D’Arcangelo, Andres Barba Joaquin, Geoffrey Liu, Lorenzo Antonuzzo, Gonzalo Fernández Hinojal, Xiuning Le, Li Zheng, Pasi A. Jänne, WU-KONG1B
Read The Full Article
